LivingGLP1
Study S001545

GLP1-Receptor Agonists in Men With Prostate Cancer: Control of Cardiovascular Risk Factors and Prostate Biomarkers

ClinicalTrials.gov record

Registration

Registration
NCT06908694
Acronym
GAINPCCONTROL
Study type
INTERVENTIONAL
Phase
PHASE4
Masking
NONE
Status
ACTIVE_NOT_RECRUITING
Enrollment
20
Start
2025-07-02
Primary completion
2027-10-31
Lead sponsor
Hamilton Health Sciences Corporation
Conditions
Prostate Cancer
Interventions
DRUG:Semaglutide Pen Injector
Results posted
FALSE
Individual participant data sharing
NO

Registered primary outcomes

  • Number of Serious Adverse Events [12 months]
  • Number of Adverse Events leading to Drug Discontinuation [6 months]
  • Measure of Weight [12 months]
  • Measure of Waist Circumference [12 months]
  • Measure of Blood Pressure [12 months]
  • Concentration of HbA1c [12 months]
  • Concentration of Lipids [12 months]
  • Concentration of PSA [12 months]
  • Concentration of Creatinine [12 months]
  • Calculation of estimated glomerular rate [12 months]
  • Number of Clinical Outcomes [12 months]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.